Investing.com - Roivant Sciences reported on Monday third quarter earnings that missed analysts' forecasts and revenue that topped expectations.
Roivant Sciences announced earnings per share of $-0.420 on revenue of $12.53M. Analysts polled by Investing.com anticipated EPS of $-0.380 on revenue of $5.7M.
Roivant Sciences shares are down 19.03% from the beginning of the year and are trading at $5.300 , down-from-52-week-high.
Roivant Sciences shares gained 2.71% in pre-market trade the report.
Roivant Sciences follows other major Healthcare sector earnings this month
Roivant Sciences's report follows an earnings beat by J&J on Tuesday, October 18, 2022, who reported EPS of $2.55 on revenue of $23.79B, compared to forecasts EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on Tuesday, November 1, 2022 with third quarter EPS of $1.98 on revenue of $6.94B, compared to forecast for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar